Exhibit 99.1 Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results Presentations at AACR Annual Meeting 2026 underscore significant opportunities for nuzefatide pevedotin in EphA2 expressing cancers, including pancreatic cancer Human imaging data provides further evidence of the potential of EphA2 as a novel cancer target and the positive properties of Bicycle radioligand molecules for radiopharmaceutical use Altogether, Bicycle Therapeutics believes that these data ...